SG Capital Management LLC purchased a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 409,104 shares of the medical instruments supplier’s stock, valued at approximately $9,205,000. OraSure Technologies accounts for approximately 1.0% of SG Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. SG Capital Management LLC owned 0.69% of OraSure Technologies as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of OraSure Technologies by 127,593.4% during the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after purchasing an additional 7,737,261 shares during the period. Vanguard Group Inc. raised its position in OraSure Technologies by 19.8% in the second quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock worth $92,390,000 after acquiring an additional 886,333 shares in the last quarter. Dimensional Fund Advisors LP raised its position in OraSure Technologies by 5.8% in the second quarter. Dimensional Fund Advisors LP now owns 3,057,690 shares of the medical instruments supplier’s stock worth $52,777,000 after acquiring an additional 167,642 shares in the last quarter. Daruma Capital Management LLC raised its position in OraSure Technologies by 2,761.0% in the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock worth $48,699,000 after acquiring an additional 2,722,886 shares in the last quarter. Finally, State Street Corp raised its position in OraSure Technologies by 6.9% in the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after acquiring an additional 106,326 shares in the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.
OSUR has been the subject of a number of research analyst reports. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Saturday, September 9th. Jefferies Group restated a “buy” rating and issued a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price objective on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, ValuEngine cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $18.21.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.09. The firm had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm’s quarterly revenue was up 31.0% on a year-over-year basis. During the same period last year, the company earned $0.11 EPS. research analysts anticipate that OraSure Technologies, Inc. will post 0.42 EPS for the current year.
In related news, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mara G. Aspinall purchased 5,000 shares of OraSure Technologies stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The disclosure for this purchase can be found here. Insiders own 6.40% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.